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ABSTRACT
Objective: To assess the efficacy of Memantine as a preventive and therapeutic intervention for migraine and
tension-type headache. Methods: This clinical trial was conducted over a period of 3 months. A total of 44 subjects,
with diagnosed migraine and/or tension-type headache, presenting to a private neurology clinic in Karachi, Pakistan
were selected through purposive sampling technique. Patients were treated with incremental doses of Memantine.
Adult patients belonging to both genders were included in the study. Data was analyzed using SPSS version 16.0 and
associations were made using Chi square test with p-value of less than 0.05 taken as significant. Results: Out of 44
patients, 35 (79.5%) were females and 9 (20.5%) were males which shows a very high occurrence of migraine and
tension-type headache in females. Average age was found to be 32.6 ≈ 33 years. Efficacy of the drug was observed
to be 81.8% which is significantly high. The baseline MIDAS score when compared with the score at 3-month follow-up
by applying Wilcoxon signed rank test showed mean ± S.D (39.52±21.27 vs. 6.72±6.41) where p=0.000 (<0.05)
which shows a highly significant result. All 44 patients were known cases of migraine while 25% (11) of them also
suffered from tension-type headache. Patients were treated with incremental doses of Memantine and were observed
for the efficacy of the drug. Patients maintained their diaries of intensity of pain, distressing influence of the pain and
how it hindered their daily routine. Results showed that intensity of pain decreased significantly by the end of the 3rd
month of treatment and majority of the patients felt less distressed on their final follow-up visit. By the end of the 3rd
month, the level of hindrance in the daily routines of the patients caused by the headache also fell significantly.
Conclusion: Memantine has significant beneficial effects in reducing intensity of pain and disability in patients with
migraine and tension type headache.
Keywords: Memantine, Migraine, Tension-type headache, Efficacy, Headache.
BACKGROUND

revolutionary drug in the treatment of chronic pain
states. Its efficacy as a neuroprotective drug has been
demonstrated through various researches (1,6,7).
Glutamate and other excitatory neurotransmitters have
been highlighted to be involved in transmission of
signals to spinal cord or brainstem in chronic pain
states. Similarly, these neurotransmitters are thought to
be involved in potentiation and augmentation of the
pain transmission cascade in chronic headache
conditions (1). Memantine has also shown potential in
addressing the issues of complex regional pain
syndrome and phantom limb pain, which suggests that
its effectiveness in relieving pain depends on the kind of
pain under consideration (8). Cognitive problems have
often been reported by patients with chronic pain
disorders. Memantine, being a glutamate receptor
antagonist, has the capacity to tackle both of these
problems (9). Furthermore, in several clinical trials,
Memantine has shown very low incidents of adverse
effects (10,11). Studies have proven that Memantine has

Memantine, an N-methyl D-aspartate (NMDA) receptor
antagonist, works through its intrinsic blockade of
afferent signals of pain transmission, known as the
glutamate system, which plays a major role in
pathophysiology of tension-type headache (TTH) and
migraine (1). Memantine works as an uncompetitive,
voltage-dependent, low affinity, open channel antagonist.
By binding to the NMDA receptor with a higher affinity
than Mg2+ ions, Memantine inhibits the prolonged
influx of Ca2+ ions, which forms the basis of neuronal
excitotoxicity. Most importantly, its dissociation rate is
relatively faster which allows it not to accumulate
substantially in the synaptic channels, hence, it does
not interfere with the normal synaptic transmission
(2,3,4,5)
. Therefore, it can be used as an effective modality
in prophylaxis and treatment for chronic pain disorders
including tension-type headache and migraine. During
the recent decade, Memantine has evolved as a
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its excellent effects on D2 receptors as well, preventing
its sensitization during a manic attack, hence it can be
used as drug of choice for bipolar disorder (12). Recent
works are being done to evaluate its effectiveness in
neurocognitive disorders such as Alzheimer’s disease
(10,11,13)
. The aforementioned wide variety of uses of
Memantine in the field of medicine has greatly
increased the interest of researchers in this
revolutionary drug. To the best of our knowledge, no
study has been conducted in our population about the
use of NMDA antagonists that could be of major interest
in regards to the pathophysiology and future treatment of
Migraine, TTH and other chronic pain disorders.

Care, a private neurology clinic in Karachi, Pakistan
were selected through purposive sampling technique.
Data was collected over a period of three months
between January 2015 and March 2015.
INCLUSION CRITERIA INCLUDED: Males and females
aged between 18 and 65 years Diagnosis of Migraine
using International Headache Society Criteria for Diagnosis of Migraine(15) Diagnosis of TTH using International Headache Society Criteria for Diagnosis of TTH(15)
Signature of Informed Consent Form. In case of females
of childbearing age, commitment not to become pregnant
during the entire duration of the study.

OPERATIONAL DEFINITIONS

EXCLUSION CRITERIA INCLUDED : Patients below the
age of 18 and above the age of 65. Patients undergoing
drug treatment for migraine or TTH. Patients already
receiving treatment will stop treatment and a washout
period of one week will be performed. During the washout
period the patient may take, if necessary, analgesics such as
Tramadol or Acetaminophen. Patients currently taking
Memantine or having taken Memantine during the 2
months prior to recruitment. Another Axis I psychiatric
disorder using Structured Clinical Interview for DSMIVAxis I Disorders (SCID-I) that may interfere with adherence to the study protocol (e.g. alcohol and/or
substance abuse/dependence, schizophrenia, chronic
delirium, acute depression etc.) Pregnancy or breastfeeding. Hypersensitivity to the active ingredient,
Memantine. Medical conditions that require special
precautions when administering Memantine according
to the summary of product characteristics: a) epilepsy
b) circumstances that may cause high urine pH owing
to Proteus urinary tract infection or renal tubular acidosis c) recent myocardial infarction, d) congestive heart
disease and e) uncontrolled arterial hypertension.
Clinically significant and active evidence of liver or
kidney disease, hematological, respiratory, endocrine or
cardiovascular disorders. Use of prescription drugs that
may cause drug interactions with Memantine: NMDAR
antagonists (amantadine, ketamine, dextromethorphan), L-Dopa, dopamine agonists and cholinergic
agonists. Use of non-permitted concomitant medication during the week prior to the recruitment or where
the patient is expected to require treatment with such
drugs: antidepressants (duloxetine, venlafaxine, mirtazapine, bupropion, SSRI, etc), analgesics (pregabalin,
gabapentin, opiates, etc).

MIGRAINE: A primary headache disorder that is benign
and recurrent, often life-long, and characterized by
attacks. Attacks include features such as Headaches,
most often described as pulsating, throbbing, unilateral
and aggravated by minor movement and routine physical
activity; typically lasting hours to 2-3 days Nausea,
photophobia and phonophobia Attack frequency ranges
from once a week to once a year (14)
TENSION-TYPE HEADACHE: A primary headache
disorder characterized by tight, band-like headaches
that occur bilaterally. These headaches may be related
to stress or associated with musculoskeletal problems
in the neck. They may last a few hours or persist for
several days with or without fluctuations.
Variable
Gender
Male
Female
Age
Efficacy of Memantine
Diagnosis
Migraine
Migraine + TTH
Migraine changing to seizures
Others
MIDAS Variables
Missed work or school (no. of days)

Frequency Mean ± S.D
(%)
9 (20.5%)
35
(79.5%)

Range(Min/max)

32.6±10.32

18/65

6.81±7.15

0/30

6.88±5.52

0/20

9.97±6.36

0/33

10.52±6.06

3/32

5.86±4.84
14.39±6.41

0/20
1/32

36
(81.8%)
20
(45.45%)
11 (25%)
3 (6.81%)
10
(22.7%)

Productivity at work/school reduced
by half (no. of days)
Could not perform household
chores (no. of days)
Productivity reduced by half in
household work (no. of days)
Missed leisure activities
Average headache days

Each patient diagnosed to have migraine and/or TTH
coming to the outpatient department was explained
about the purpose of the study including the risks and
benefits of participation in the study. After obtaining
signed consent, intervention was started. Patients
received 20 mg of Memantine (2 tablets of 10 mg

TABLE 1: Baseline characteristics
MATERIALS AND METHODS
A total of 44 subjects, with diagnosed migraine and/or
tension-type headache, presenting to Neuro Clinic and
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each).

anchored by word descriptors at each end (no interference and extreme interference). Disability caused by
the pain. It will be evaluated with the Migraine Disability
Assessment Test (MIDAS). MIDAS is a 5-item questionnaire
to measure the health status and level of disability
caused by the pain in patients with headache disorders.

The dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily

INTERPRETATION: 0-5 – MIDAS Grade I (Little or no
disability) 6-10 – MIDAS Grade II (Mild disability) 11-20
– MIDAS Grade III (Moderate disability) ≥ 21 – MIDAS
Grade IV (Severe disability).

From the 4th week up to the 12th week: 20 mg daily
Patients kept headache diaries for migraine and TTH, as
well as pain scores. Patients were followed up initially at
1st week, 2nd week, then every month for a total of
three months. On each follow-up visit, pain rating scale
and MIDAS questionnaire was filled and patients were
observed for the efficacy of the drug.

How intense is your pain now?
No pain
Mild
Moderate
Severe
Extreme
How intense was your pain on average last week?
No pain
Mild
Moderate
Severe
Extreme
How distressing is your pain now?
No distress
Mild
Moderate
Severe
Extreme
How distressing was your pain on the average last
week?
No distress
Mild
Moderate
Severe
Extreme
How much does your pain interfere with your
normal activities?
No interference
Mild
Moderate
Severe
Extreme
Variables
Mean±S.D

At baseline

At 3 month
follow-up
Frequency (%)

0
0
4 (9.1)
15(34.1)
25(56.8)

1 (2.3)
15 (34.1)
19 (43.2)
8 (18.2)
1 (2.3)

0
0
13 (29.5)
15 (34.1)
16 (36.4)

1 (2.3)
11 (25)
18 (40.9)
13 (29.5)
1 (2.3)

0
2 (4.5)
(31.8)
6 (13.6)
(45.5)
25 (56.8)
11 (25)

3 (6.8)
14

6 (13.6)
1 (2.3)

0
3 (6.8)
7 (15.9)
25 (56.8)
9 (20.5)

2 (4.5)
16 (36.4)
18 (40.9)
7 (15.9)
1 (2.3)

0
1 (2.3)
12 (27.3)
(31.8)
26 (59.1)
5 (11.4)
p-value

2 (4.5)
22 (50)
14

Baseline score vs. follow-up 39.52±21.27 vs. 6.72±6.41
at 3 months

FIGURE 1: GENDER DISTRIBUTION AMONG SUBJECTS
Gender
40

Frequency

Variable

SPSS version 16.0 was used for statistical analysis.
Separate frequencies and percentages were calculated
for categorical variables. Association was assessed
through Chi square test and p-value ≤ 0.05 was taken
as significant.

20

20

35

10
9
0

Male

Female

Gender

RESULTS

5 (11.4)
1 (2.3)

Out of 44 patients, 35 (79.5%) were females and 9
(20.5%) were males which shows a very high
occurrence of migraine and tension-type headache in
females (Figure 1). The mean age of the subjects was
found to be 32.6 ≈ 33 years. Our subjects were
classified according to the type and nature of chronic
headache. Comprising of migraine alone, migraine
along with tension-type headache, migraine changing
to seizures and others, in coherence with other
studies.16 All 44 patients were known cases of
migraine while 25% (11) of them also suffered from
tension-type headache as shown in Table 1. An initial
daily dose of 5 mg of Memantine was started for 1 week
with weekly dose increase of 5 mg up to a maximum
dose of 20 mg per day, as tolerated. Patients were
asked to maintain a headache diary of intensity of pain,
distressing influence of the pain and how it hindered
their daily routine in order to keep an account of

0.000

TABLE 2: Intensity of pain, frequency of distress and
interference at baseline and at 3 months follow-up
OUTCOME MEASURES
Improvement in clinical variables. Intensity of pain. It
will be evaluated using Pain Rating Scale. It is a horizontal line, 10 cm in length, anchored by word descriptors
at each end (no pain and extreme pain). Level of
distress caused by the pain. It will be evaluated with
Pain Rating Scale. It is a horizontal line, 10 cm in
length, anchored by word descriptors at each end (no
distress and extreme distress). Interference of pain with
normal daily activities. It will be evaluated with Pain
Rating Scale. It is a horizontal line, 10 cm in length,
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effectiveness of the drug in every individual. On each
follow-up visit, pain rating scale and MIDAS
questionnaire was filled and patients were observed for
the efficacy of the drug. Efficacy of the drug was found
to be 81.8% which is significantly high. The baseline
MIDAS score when compared with score at 3-month
follow-up by applying Wilcoxon signed rank test showed
mean ± S.D (39.52±21.27 vs. 6.72±6.41) where
p=0.000 (<0.05) which shows a highly significant
result as shown in Figure 2. Results in Table 2 show that
intensity of pain decreased significantly by the end of
the 3rd month of treatment, with only 2.3% of the
patients complaining of extreme pain at the final
follow-up at 3 months while 56.8% of the patients
complained of extreme pain at the initial visit. Majority
of the patients felt less distressed on their final
follow-up visit at 3 months. 6.8% of the patients had
no distress or discomfort at the final follow-up. By the
end of the 3rd month, the level of hindrance caused by
the headache in the daily routines of the patients also
fell significantly, with only 2.3% of the patients
complaining of extreme interference of pain with normal
daily activities at the 3-month follow-up.

receptors that are excitatory amino acids and play an
intrinsic role in pain transmission, long-term
potentiation and central sensitization. Therefore,
blockade of NMDA receptors helps in reducing the
central barrage of afferent signals that may be involved
in the maintenance of chronic headache states. As in
other similar researches (1), the participants in our study
mainly comprised of females (79.5% vs 20.5%),
proving a worldwide female dominance in incidence of
migraine and tension-type headache. The ages of our
patients ranged from 16 to 65 years. It is reasonable to
expect migraine symptoms to improve as patients get
older, however, many people continue to have migraine
attacks in older age and considerable number of people
with migraine in later life exist in many populations
worldwide. According to The Migraine Trust, “many
migraine sufferers contacting The Migraine Trust have
said that they expected their migraines to get better as
they got older. Unfortunately this is not the case for
everyone. There are many people with migraine in their
60s, 70s, and 80s.(17) Dr. Vincent Martin, professor of
medicine and co-director of the Headache and Facial
Pain Program at the University of Cincinnati says
headaches increase by 50 to 60 percent in women with
migraine during perimenopausal and menopausal time
periods.(18) Biqal and Rapoprt, in their study on
Memantine in the preventive treatment of refractory
migraine, reported a decrease in headache frequency
from 21.8 days at baseline to 16.1 days at 3 months (p
<0.01) as well as a significant reduction in mean
disability scores at the final follow-up at three months
which correlates with the results of our study(9). In our
study, the baseline disability score when compared with
the score at 3-month follow-up by applying Wilcoxon
signed rank test showed mean ± S.D (39.52±21.27
vs. 6.72±6.41) where p=0.000 (<0.005) which
shows a highly significant result. Similarly, a randomized,
double-blind, placebo-controlled, cross-over trial
demonstrated a significant reduction in intensity of
headache on a 0-10 verbal rating scale(16). In our study,
the intensity of headache decreased considerably by the
end of three months with only 2.3% of the patients
complaining of extreme pain at the final follow-up visit
at 3 months compared to 56.8% of the patients
complaining of extreme pain at the initial visit.
Furthermore, at the final follow-up visit, 2.3% of the
patients were entirely relieved of the pain. In his
preliminary open-label study conducted on 30 patients
with chronic refractory headache disorders, Krusz
reported a 58% and 52% decrease from the baseline in
the frequency of migraine and tension-type headache
respectively at the end of one month, which gives a
similar proportion as in our study (1). As per patients
self-reporting in their headache diary, the interference
of headache with routine work markedly reduced in

Wilcoxon signed rank test p>0.005
40.00

Average score

30.00

20.00

39.52

10.00

6.73

Figure
0.002:

Baseline.score

follow up after 3 months

DISCUSSION
This study sought to explain the efficacy of Memantine
in the treatment of migraine and tension-type
headache. A number of studies have elucidated that
Memantine, a low-affinity antagonist to NMDA
glutamate receptors that are thought to be intrinsic to
pain transmission, is effective in the treatment and
prophylaxis of migraine and tension-type headache.(1,6,9,16)
Memantine works by blocking NMDA glutamate
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frequency from 59% to 40% (p<0.005). When patients
reported at 3 months follow-up, there was a significant
reduction in frequency of occurrence of symptoms,
statistically proven as 39.52±21.27 vs. 6.72±6.41
(baseline vs. follow-up). According to a meta-analysis,
Memantine may be a reasonable option for the
prevention of primary headache disorders as it lowered
the frequency and intensity of migraine headaches and
demonstrated only few adverse effects, which is in
correlation with our study (19). For Memantine to be
utilized as an abortive treatment, more evidence in the
form of randomized, double-blinded, placebo-controlled
clinical trials comparing Memantine with a standard
abortive treatment will be needed. In our study, none of
the patients developed significant adverse effects to
warrant exclusion from the study. Efficacy of the drug, in
our study, was observed to be 81.8% at the end of
three months but more Phase 2 and 3 clinical trials are
needed before the definitive duration of treatment can
be established.

6
7.

8.

9.
10.

CONCLUSION

11.

Memantine is an effective drug for the prophylactic
treatment of migraine and tension-type headache in terms
of reducing intensity of pain and improving the quality of life.
A randomized, placebo-controlled, double-blind clinical trial is
needed to confirm our observations.
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